SAN FRANCISCO, Nov. 2, 2016
SAN FRANCISCO, Nov. 2, 2016 /PRNewswire/ -- Symic Bio, a clinical-stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the 22nd Annual BIO Europe Conference in Cologne. The presentation will take place within the autoimmune/inflammation track.
Conference details are as follows:
Date: Tuesday, Nov. 8, 2016
Time: 3:00 p.m. CET
Location: Rheinsaal 4, Level 2, Koelnmesse - Congress Center North, Cologne, Germany
About Symic Bio
Symic Bio is a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, one for the treatment of critical limb ischemia (SB-030) and one directed at disease-modification in the treatment of osteoarthritis (SB-061). In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
Lisa Burns or Bill Slattery, Jr.
Burns McClellan, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-the-22nd-annual-bio-europe-conference-300353369.html
SOURCE Symic BioPR Newswire
Last updated on: 02/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.